NCT00447694View on ClinicalTrials.gov

Cardiac T2* in Beta-thalassemia Patients on Deferasirox Treatment

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

November 30, 2009

Study Completion Date

November 30, 2009

Conditions
Beta-thalassemiaIron Overload
Interventions
DRUG

Deferasirox

Oral deferasirox 30mg/kg/day once per day for 77 weeks.

Trial Locations (3)

60614

Children's Memorial Hospital, Chicago

90027

Childrens Hospital of Los Angeles, Los Angeles

94609

Children's Hospital and Research Center at Oakland, Oakland

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY